Adherence to insulin pen therapy is associated with reduction in healthcare costs among patients with type 2 diabetes mellitus

American Health and Drug Benefits

Volumn 8, Issue 3, 2015, Pages 148-158

  Chandran, Arthi ^a   Bonafede, Machaon K ^b   Nigam, Sonali ^a   Saltiel Berzin, Rita ^c   Hirsch, Laurence J ^d   Lahue, Betsy J ^a  

^a IMS Health   (United States)

^b IBM WATSON HEALTH   (United States)

^c Department of Medical Affairs ^*  (United States)

^d Diabetes Care Department of Medical Affairs   (United States)

Author keywords

Diabetes management; Healthcare cost; Insulin adherence; Insulin pen; Medical costs; Pharmacy costs; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; CLINICAL FEATURE; DESCRIPTIVE RESEARCH; DIABETIC NEUROPATHY; DYSLIPIDEMIA; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL COST; HUMAN; HYPERTENSION; INSULIN INJECTION PEN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; YOUNG ADULT;

EID: 84930893625     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. American Diabetes Association. Standards of medical care in diabetes— 2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
2. Ford ES. Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999-2008. J Diabetes. 2011;3:337-347.
3. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368:1613-1624.
4. National Committee for Quality Assurance. Improving quality and patient experience: the state of healthcare quality 2013. www.ncqa.org/Portals/0/Newsroom/SOHC/2013/SOHC-web_version_report.pdf. Accessed May 7, 2015.
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438-447.
6. Kurtz SMS. Adherence to diabetes regimen: empirical status and clinical applications. Diabetes Educ. 1990;16:50-56.
7. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5A):27S-34S.
8. Xie L, Zhou S, Wei W, et al. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2013;15:230-236.
9. Chandran A, Bonafede MK, Nigam S, et al. Adherence to insulin pen therapy is associated with reduction in healthcare costs among patients with type 2 diabetes mellitus. Am Health Drug Benefits. 2015;8:148-158.
10. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149.
11. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14:71-75.
12. Tan AM, Muthusamy L, Ng CC, et al. Initiation of insulin for type 2 diabetes mellitus patients: what are the issues? A qualitative study. Singapore Med J. 2011;52:801-809.
13. Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26:416-424.
14. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011;17:845-852.
15. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86:44-57.
16. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparisons of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28:437-443.
17. Mitigating the burden of type 2 diabetes: challenges and opportunities. Am Health Drug Benefits. 2015;8 (suppl 1):S1-S23.